ArticleTranslational vision science & technology2026
Circulating eNAMPT in Glaucoma: A Semi-Quantitative Plasma Analysis Before and After Nicotinamide Supplementation.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Glaucoma is characterized by progressive retinal ganglion cell degeneration. Nicotinamide supplementation has demonstrated neuroprotective potential in glaucoma by raising retinal and optic nerve nicotinamide adenine dinucleotide (NAD) via the salvage pathway, dependent on nicotinamide phosphoribosyltransferase (NAMPT). The NAMPT is essential for retinal function, and its extracellular form (eNAMPT) has been detected in blood. Reduced circulating eNAMPT could indicate impaired NAD biosynthetic capacity and glaucomatous neurodegeneration susceptibility. Methods: We (i) developed a specific, semiquantitative assay to detect plasma eNAMPT, (ii) explored its potential as biomarker, and (iii) assessed the effect of 2-week nicotinamide supplementation on circulating levels. This was done in samples from a prospective clinical trial at the Eye Clinic, Umeå University Hospital (Sweden), including 30 controls and 90 patients with glaucoma. Results: A Western blotting assay was designed, detecting eNAMPT (52 kilodalton [kDa]) and transferrin (77 kDa) as housekeeping protein from 0.2 µL EDTA-plasma. Intra- and inter-assay variability were 14.9% and 37.9%, respectively. eNAMPT levels showed no difference between glaucoma and controls, nor changes after supplementation. Conclusions: eNAMPT is readily and specifically detected by Western blotting in plasma from healthy controls and patients with glaucoma. Given the role of NAD/NAMPT in neurodegeneration, this study provides a platform for specific detection of eNAMPT in liquid biopsies. Further studies specifically designed to study eNAMPT are needed to clarify its role in retinal ganglion cell degeneration and the therapeutic response to nicotinamide. Translational Relevance: This study established a method to sensitively detect plasma eNAMPT of patients with glaucoma and controls, providing a basis for future biomarker development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.